Modified Intermediate-Dose Cytarabine Combined with Daunorubicin Induction and Re-Induction Protocol Use in Patients with Acute Myeloid Leukemia
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 4
Abstract
Background A prospective study was conducted to investigate the response rate of patients newly diagnosed with acute myeloid leukemia (AML) to modified intermediate-dose cytarabine with daunorubicin. Methods A total of 45 patients received cytarabine at a modified intermediate-dose (115 mg/m<sup>2</sup>) given by continuous intravenous infusion for 12 hours twice daily over 7 days and daunorubicin 45 mg /m<sup>2</sup> given on days 1, 2, and 3 of induction therapy. Patients with a complete response received reinduction with cytarabine at the same dose and infusion over 5 days with 2 doses of daunorubicin. After remission, patients who were socioculturoeconomically eligible for transplantation were evaluated for other prognostic factors, except for cytogenetic factors that were not available in the study center, to identify patients that were eligible for stem cell transplantation. Results Patients were 17 to 60 years of age. 6 patients had early death due to complications and treatment failure. 39 patients (87%) achieved complete remission. Only 16 patients were eligible for transplantation on evaluation and underwent allogeneic stem-cell transplantation. 18 patients were not eligible for this transplantation and underwent consolidation therapy with chemotherapy. 5 patients did not receive any treatment and died during the follow up. In the follow up period between April 2006 and January 2014 in 39 out of 45 patients (min 0.2 yr, max 7. 8 yr) 31 % of patients were alive. Conclusions Modified intermediate dose cytarabine was effective for the treatment of AML, achieving a high rate of complete remission, and might improve outcomes in patients.
Authors and Affiliations
Mozaffar Aznab, Omid Beiki
Keywords
Related Articles
- EP ID EP237355
- DOI 10.5812/ijcm.7000
- Views 54
- Downloads 0
No Association Between Human Papillomavirus and Prostate Cancer
Background: The role of human papillomavirus (HPV) in prostate cancer is unclear. The aim of this study was to investigate the relationship between HPV and prostate cancer. Methods: In this case - control study, 133 par...
A Comparative Study of FIGO 1988 Versus 2009 Staging for Endometrial Carcinoma
Objectives: The aim of this study was to investigate the benefits of the newly revised “The international federation of gynecology and obstetrics (FIGO), 2009” sytem and whether there was a difference in new system compa...
The Effect of Para Aortic Lymph Node Dissection in Staging and Complete Cytoreductive Surgery of Ovarian Cancer
Objective: Lymphatic spread is a common feature of ovarian cancer both in early and advanced stages of the disease. There is also a controversial problem of the impact of para-aortic lymph node dissection between gynecol...
Comparison of Surgical Margin After Breast Cancer Surgery Between Oncoplastic Technique and Conventional Breast-Conserving Surgery
Background: Compared to other breast surgery methods, the accurate determination of pathologic margin in oncoplastic technique can affect its development and further employment of this technique. The current study aimed...
A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran
Background: Breast carcinoma is not a homogenous disease. It is divided into 5 pathological subtypes of luminal1, luminal2, strongly Her2 positive, basal like, and normal breast like. Basal like breast carcinoma that acc...